Cempra (CEMP) announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) seeking approval of oral capsule and intravenous formulations of solithromycin for the treatment of community-acquired bacterial pneumonia. The review process is now underway. An opinion by the advisory Committee for Medicinal Products for Human Use (CHMP) will be issued within 210 days.